Prothena Corporation plc reported $55M of revenue over the trailing twelve months, +427% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $55M (to Q2 2026). Net income: −$44M, trailing twelve months to Q2 2026. Free cash flow: −$61M, trailing twelve months to Q2 2026. Operating margin: −29737%, trailing twelve months to Q2 2026.

PRTAProthena Corporation plc

Healthcare

$8.61-15% 1Y

$8.61

$7.9152 weeks$11.51

PRTA as reported

Prothena Corporation plc reported $55M of revenue over the trailing twelve months, +427% on the year before. 8 reported series are charted on this page, each one as filed.

$55M

Revenue, trailing twelve months · to Q2 2026 · +427% against the twelve months before

Net income: −$44M
Net income · −85% year on year · trailing twelve months to Q2 2026
Free cash flow: −$61M
Free cash flow · −69% year on year · trailing twelve months to Q2 2026
Operating margin: −29737%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for PRTA, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$55M	+427%	Q2 2026
Net income	−$44M	−85%	Q2 2026
EPS	−$0.84	−85%	Q2 2026
Operating margin	−29737%	n/a	Q2 2026
Net margin	−26523%	n/a	Q2 2026
ROE	−61%	n/a	Q2 2026
ROA	−53%	n/a	Q2 2026
Free cash flow	−$61M	−69%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.